Abstract
The maintenance of bacterial cell shape and integrity is largely attributed to peptidoglycan, a biopolymer highly cross-linked through d,d–transpeptidation. Peptidoglycan cross-linking is catalyzed by Penicillin-Binding Proteins (PBPs) that are the essential target of β-lactam antibiotics. PBPs are functionally replaced by l,d–transpeptidases (Ldts) in ampicillin– resistant mutants of Enterococcus faecium and in wild-type Mycobacterium tuberculosis. Ldts are inhibited in vivo by a single class of β-lactams, the carbapenems, which act as a suicide substrate. We present here the first structure of a carbapenem–acylated l,d–transpeptidase, E. faecium Ldtfm acylated by ertapenem, which revealed key contacts between the carbapenem core and residues of the catalytic cavity of the enzyme. Significant reorganization of the antibiotic conformation occurs upon enzyme acylation. These results, together with the analysis of protein–to–carbapenem proton transfers, provide new insight into the mechanism of Ldt acylation by carbapenems.
The peptidoglycan, an essential component of the bacterial cell wall, plays key roles in the maintenance of bacterial shape, in the resistance to osmotic pressure from the cytoplasm, and in the formation of daughter cells during cell division. As inhibition of peptidoglycan synthesis leads to bacterial cell lysis or death, its biosynthesis machinery is the favorite target of various antibiotics, including β-lactams. The latter drugs irreversibly inactivate d,d– transpeptidases, also referred to as penicillin-binding proteins (PBPs), that catalyze the last cross-linking step of peptidoglycan polymerization (1). In Enterococcus faecium, PBPs catalyze formation of 4→3 cross–links, which connect the carbonyl of d–Ala at the 4th position of a donor stem peptide to the amine of the d–iAsn side–chain at the 3rd position of an acceptor stem peptide (d–Ala4→d–iAsn–l–Lys3 cross–links). The transpeptidation reaction involves an intermediate esterification between the PBP active–site serine and the d– Ala4 carbonyl after cleavage of the d–Ala4–d–Ala5 peptide bond of the donor stem peptide and release of d–Ala5. The nucleophilic serine can also be acylated by β–lactams, which act as suicide substrates, form stable acylenzymes, and thereby irreversibly inactivate the PBPs. A new class of enzymes, the active–site cysteine l,d–transpeptidases (Ldts), was identified in β– lactam–resistant mutants of E. faecium selected in vitro (2) and in wild–type strains of Mycobacterium tuberculosis (3), Mycobacterium abscessus (4), and Clostridium difficile (5). The l,d–transpeptidation pathway involves an essential d,d–carboxypeptidase that cleaves the d–Ala4–d–Ala5 bond of peptidoglycan precursors and generates the tetrapeptide stems used as the acyl donor in the cross–linking reaction (6). In E. faecium, the Ldt forms l–Lys3→d– iAsn–l–Lys3 cross–links following cleavage of the l–Lys3–d–Ala4 peptide bond of the donor stem tetrapeptide. Ldts are inactivated by a single β–lactam class, the carbapenems, which form a thioester bond with the active–site cysteine (7-9). The carbapenem class includes four approved drugs, imipenem, ertapenem, doripenem, and meropenem, with similar structure and the same mode of action (10).
The crystal structures of Ldts from E. faecium (Ldtfm) (11), Bacillus subtilis (LdtBs) (12), and M. tuberculosis (LdtMt2) (13) have been determined but crystallization of β–lactam– acylated forms of these enzymes has been unsuccessful. Recently, we have reported the NMR structure of LdtBs and we showed that acylation of this enzyme by imipenem induces substantial conformational flexibility in large regions of the protein (14). The dynamics of the acylenzyme prevented the determination of a unique structure and the conformation of the drug in the active site could not be accurately obtained. To gain insight into the mechanism of acylation of l,d–transpeptidases by β–lactams, we have solved the NMR structure of E. faecium Ldtfm acylated by ertapenem. This first high–resolution structure of a carbapenem– acylated l,d–transpeptidase provides clues on antibiotic accessibility, antibiotic–enzyme stabilizing interactions, and gives new insights into the mechanism of the acylation reaction.
The X–ray structure of a fragment of Ldtfm (residues 217 to 466) was solved in the absence of antibiotic (11). This structure revealed the presence of two domains, an elongated N–terminal domain with a mixed α–β fold (residues 217 to 338), and a C–terminal catalytic domain (ErfK_YbiS_YhnG domain; Pfam PF03734). The NMR structural studies presented here were performed on the catalytic domain (residues 341 to 466), which displayed the same catalytic properties as the entire protein (Supporting Table S1). Since the X–ray structure showed the presence of zinc and sulfate ions from crystallization conditions in the active site of this enzyme, the NMR solution structure of the catalytic domain of Ldtfm was solved de novo. To refine the structure of the active site, protonation states of active–site residues were investigated by pH–titration, using 1H,13C–HSQC and 1H,15N–SOFAST–HMQC spectra centered on aromatic and histidine imidazole rings, as previously described for the B. subtilis enzyme (14). These analyses revealed a pKa lower than 4.6 for conserved His421, which exists as the Nδ1 tautomer in the unprotonated form, and a pKa superior to 9.9 for catalytic Cys442 (Supporting Figure S1). These protonation states are similar to those found in the B. subtilis enzyme (14) and confirm the participation of Cys442 to a catalytic triad that comprises His421 and Asp422 (11).
The protonation states were included into the structure calculation protocol. The superposition of the 10 lowest energy NMR structures of Ldtfm is shown in Figure 1a. The root–mean–square deviations (RMSDs) for backbone and heavy atoms, as calculated from the 20 lowest energy structures, are 0.35 and 0.44 Å, respectively (see Supporting Table S2 for further statistical analysis). These values indicate a remarkable convergence towards a well– defined structure. As expected, the NMR structure and the X–ray structure of the E. faecium catalytic domain (11) are very similar, with an RMSD of 1.03 Å over all backbone heavy atoms in common. The NMR structure is also similar (RMSD of 1.36 Å on backbone heavy atoms) to a recently published X-ray structure (13) of M. tuberculosis, LdtMt2 (Supporting Figure S2), suggesting that the results of the present work extend to the l,d–transpeptidase of this pathogenic bacterium.
The NMR structure of the E. faecium catalytic domain acylated by ertapenem was solved after complete assignment of 1H, 13C, and 15N resonances and collection of 3,016 total NOE distance restraints including 27 drug–protein constraints. The 20 lowest energy NMR structures of the acylenzyme (see Figure 1b for the superposition of the 10 lowest energy structures) overlay with an RMSD of 0.23 and 0.59 Å for backbone and heavy atoms, respectively. A statistical analysis of 20 structures after water refinement is presented in Supporting Table S2. A comparison of the structures from the apoenzyme (Figure 1a) and acylenzyme (Figure 1b) does not reveal any significant conformational rearrangement of the protein backbone (RMSD of 1.24 Å) with the exception of the loop connecting strands β8 and β9 (residues 413 to 418) highlighted in magenta.
As proposed by Biarrotte–Sorin et al. (11), the catalytic cysteine of Ldtfm is accessible from two sides of the protein. The first accessibility pocket (Pocket 1) is located between strand β6 and the loop connecting strands β8 and β9 (Figure 1c). The second accessibility pocket (Pocket 2) is located between strand β7 and a portion of the long loop connecting strands β9 to β10. The NMR structure of the acylenzyme reveals that ertapenem gets access to the cysteine from Pocket 1. This conclusion can be extended to other carbapenems based on NMR chemical shift perturbations observed with imipenem, doripenem and meropenem (Supporting Figure S3). Since carbapenems are thought to be structure analogues of the l– Lys3–d–Ala4 extremity of the acyl donor (15), Pocket 1 is proposed as the binding site for the donor stem peptide during the peptidoglycan cross–linking reaction. Pocket 2 is the proposed binding site for the acceptor stem peptide, in agreement with the detection of a peptidoglycan fragment in the X–ray structure of M. tuberculosis LdtMt2 (13).
The structure of Ldtfm acylated by ertapenem reveals a good resolution of the 4-methyl-5-(2-oxoethyl)-4,5-dihydro-1H-pyrrole-2-carboxylate originating from the carbapenem core of the drug (Figure 2a) with a RMSD of 0.7 Å on all heavy atoms (Figure 1b). The hydroxyethyl side chain (R1, Figure 2a), common to all carbapenems, is oriented towards the buried portion of Pocket 1 and is also very well defined. In contrast, the bulky pyrrolidine-2-carboxylic acid-(3-carboxyphenyl)-amide R2 side–chain of ertapenem (Figure 2a) is solvent–exposed and adopts multiple orientations in the final structure ensemble. The absence of detectable interactions between protein residues and the R2 side–chain is in agreement with previous kinetics analyses that showed little impact of R2 variations on the rate constants of the acylation reaction (7).
The conformation of ertapenem in the acylenzyme is stabilized by a limited number of hydrogen bonds connecting the side chains of Tyr403 and His440 to the Δ2-pyrroline ring of the carbapenem and the backbone amide of Gly441 to the carbonyl of the drug–Ldtfm thioester group (Figure 2b–d). The ertapenem conformation is further stabilized by multiple hydrophobic interactions involving Leu393, Trp410, Gly417, Val418, and Gly419. Among these interactions, hydrophobic contacts between the antibiotic and residues 417–419 may be responsible for the conformational rearrangement of the loop connecting strands β8 and β9 upon Ldtfm acylation by ertapenem (Figure 1).
Acylation of Ldtfm by ertapenem leads to rupture of the bond between the nitrogen and the carbonyl carbon of the β–lactam ring (designated NAJ and CAA in Figure 2b, respectively). To get further insight into the modifications of the drug conformation associated with the rupture of the NAJ-CAA bond, we modeled ertapenem with a closed β–lactam ring, referred to as “closed ertapenem”, in the catalytic cavity of Ldtfm. A structure of “closed ertapenem” was built using the PRODRG software (16). The atoms of the Δ2-pyrroline ring of the carbapenem from the “closed ertapenem” molecule were docked onto the corresponding atoms of the opened ertapenem present in the acylenzyme structure. The structure was refined with CNS (17) in a molecular dynamics simulation with explicit solvent using a distance restraint of 1.7 Å between the Sγ of catalytic Cys442 and the CAA carbonyl carbon of the β– lactam ring. Comparison of the drug conformation in the “closed ertapenem” model and in the acylenzyme indicated that rupture of the β–lactam CAA–NAJ bond increases the CAD–CAB– CAA angle by 60° and changes the CAA–NAJ distance from 1.3 to 2.8 Å (Figure 3). This structural rearrangement is required to generate the stabilizing drug–protein hydrogen–bond interactions in the acylenzyme (Figure 2b), including interactions between the pyrroline ring of ertapenem and Tyr403 and His440 residues of Ldtfm, and interactions between the backbone amide of Gly441 and the thioester carbonyl of the drug–Ldtfm covalent complex. This atomic reorganization disrupts the predicted hydrogen bond (2.9 Å) between the OAT atom of the carboxylate group of the antibiotic and the backbone amide of Gly441 (Supporting Figure S4).
The rupture of the CAA–NAJ bond of the β–lactam ring is accompanied by a proton capture. The origin of this proton is unknown in l,d–transpeptidases. In the case of the B. subtilis enzyme, the Nε2 of the catalytic histidine was previously proposed to be the proton donor (14). In the case of Ldtfm, it is unlikely that the catalytic histidine plays this role since the distance between the β–lactam NAJ nitrogen and the catalytic His421 Nε2 is too large (5.9 Å) in the “closed ertapenem” model, and even larger (6.9 ± 0.2 Å) in the acylenzyme (Figures 4b and 4c, respectively). The structure of the acylenzyme revealed His440 and Tyr403 as potential proton donors, although a water molecule cannot be excluded. The NAJ nitrogen of the β–lactam ring may be protonated prior to or after conformational alteration of ertapenem. In the latter case, the hydroxyl of Tyr403 is an excellent candidate as it is appropriately located at 2.8 ± 0.1 Å from NAJ in the acylenzyme structure. In this scenario, acylation of Ldtfm by ertapenem is expected to be, in part, thermodynamically driven by the hydrogen–bonding interactions generated by the conformational modification of the drug.
In conclusion, the high–resolution experimental and model structures proposed in the present study for the E. faecium l,d–transpeptidase apoenzyme, oxyanion intermediate and acylenzyme unravel a sequence of mechanistic events along the acylation reaction. The position of the carbapenem core has been assigned to one of the two pockets from which the Ldtfm active site is accessible. This pocket is likely to accommodate the tetrapeptide donor stem during the cross-linking reaction with natural substrates. Future challenges include exploiting key features of the inhibition mechanism to assist drug design.
Methods
Production and purification of Ldtfm
A 13C,15N–labeled protein containing the catalytic domain (residues 341 to 466) of E. faecium Ldt was produced in Escherichia coli BL21 (DE3) cells harboring the pETTEVΩldtfm plasmid in M9 minimal medium containing 13C–glucose and 15NH4Cl. The protein was purified by metal–affinity and size–exclusion chromatographies as previously described (18). The purified protein was cleaved with a 6His–labeled TEV protease leaving three extra GHM residues at the N-terminal of the catalytic domain. The polyhistidine tag (MHHHHHHENLYFQ) and the TEV protease were removed using a NiNTA affinity resin.
NMR spectroscopy
NMR samples were prepared in 100 mM sodium phosphate buffer, pH 6.4 containing 300 mM NaCl and 10% D2O. Data for structure determination were collected on 0.9 mM 13C,15N–labeled protein samples for both apo– and acyl–enzymes. To generate the latter, ertapenem (INVANZ) was incubated with Ldtfm at a drug–to–protein molar ratio of 1. The NMR data were collected at 25 °C on 600 MHz and 800 MHz Agilent Direct Drive spectrometers and on a 950 MHz Bruker Avance spectrometer. All spectrometers were equipped with triple resonance cryogenic probes. Backbone sequential resonances were assigned using 3D heteronuclear experiments. 3D 15N–NOESY–HSQC (mixing time τm = 150 ms), 3D aliphatic 13C–NOESY–HSQC (τm = 130 ms) in H2O and 3D aromatic 13C–NOESY–HSQC (τm = 130 ms) in D2O were recorded to extract distance restraints. Proton assignment of ertapenem when bound to Ldtfm was performed using intramolecular NOEs measured with the 2D 13C,15N–filtered NOESY experiment (19) recorded in D2O (τm = 180 ms). According to these data (Supporting Figure S5), the Δ2-pyrroline isomer of the ertapenem was selected and introduced into the structure calculation protocol. This experiment was also used to obtain NOEs between unlabeled ertapenem and 13C,15N–labeled Ldtfm in the acylenzyme.
Structural restraints
Secondary structure elements were identified by analysis of 13C– chemical shifts and phi/psi dihedral angular restraints were derived with TALOS+ (20). The automatic peak–picking and NOE assignment of the 15N–NOESY–HSQC, aliphatic and aromatic 13C–NOESY–HSQC spectra were performed using the iterative procedure of UNIO'10 (21). Peak–picking and assignment of the 2D 13C,15N–filtered NOESY experiment were performed manually.
Structure calculations
ARIA 2.3 (22) was run with 7 iterations calculating 100 structures, and a last cycle including 1000 structures. The 20 structures with lowest energy were subsequently refined with CNS (17) using explicit solvent in a molecular dynamics simulation. For the acylenzyme, the PRODRG web–server (16) was used to create the initial coordinates, topology and parameter files of the ertapenem–bound–cysteine, which was then introduced in the ARIA distribution. A similar procedure was used to create the “closed ertapenem” initial files that were introduced into CNS for energy minimization. No specific hydrogen bond restraint was introduced during the structure calculation. The CING webserver (23) was used for analysis of the structural ensembles and quality assessment of the structural data reported in Supporting Table S2.
Supplementary Material
Acknowledgments
This work was supported by the Agence National de la Recherche (ANR), Project CARBATUB (N° ANR 2011 BSV5 024 01) and the National Institute of Allergy and Infectious Diseases (Grants RO1 AI046626). Financial support of the French TGIR-RMN is acknowledged for conducting the research on the 950 MHz spectrometer of the ICSN Facility.
Footnotes
Notes: The authors declare no conflict of interest.
Accession codes: Coordinates of twenty structures of the Ldtfm apoenzyme and ertapenem–acylenzyme have been deposited in the Protein Data Bank (PDB) under the accession codes 3ZG4 and 3ZGP, respectively. Chemical shifts and relaxation data have been deposited in the BioMagResBank (BMRB) under accession numbers 18900 and 18911.
Supporting Information Available: Supporting information contains five figures and two tables, as well as additional references. This material is free of charge via the Internet at http://pubs.acs.org/.
References
- 1.Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol Rev. 2008;32:361–385. doi: 10.1111/j.1574-6976.2007.00095.x. [DOI] [PubMed] [Google Scholar]
- 2.Mainardi JL, Fourgeaud M, Hugonnet JE, Dubost L, Brouard JP, Ouazzani J, Rice LB, Gutmann L, Arthur M. A novel peptidoglycan cross-linking enzyme for a β-lactam-resistant transpeptidation pathway. J Biol Chem. 2005;280:38146–38152. doi: 10.1074/jbc.M507384200. [DOI] [PubMed] [Google Scholar]
- 3.Lavollay M, Arthur M, Fourgeaud M, Dubost L, Marie A, Veziris N, Blanot D, Gutmann L, Mainardi JL. The peptidoglycan of stationary-phase Mycobacterium tuberculosispredominantly contains cross-links generated by l,d-transpeptidation. J Bacteriol. 2008;190:4360–4366. doi: 10.1128/JB.00239-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lavollay M, Fourgeaud M, Herrmann JL, Dubost L, Marie A, Gutmann L, Arthur M, Mainardi JL. The peptidoglycan of Mycobacterium abscessusis predominantly cross-linked by l,d-transpeptidases. J Bacteriol. 2011;193:778–782. doi: 10.1128/JB.00606-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Peltier J, Courtin P, El Meouche I, Lemee L, Chapot-Chartier MP, Pons JL. Clostridium difficilehas an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-3 cross-links. J Biol Chem. 2011;286:29053–29062. doi: 10.1074/jbc.M111.259150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sacco E, Hugonnet JE, Josseaume N, Cremniter J, Dubost L, Marie A, Patin D, Blanot D, Rice LB, Mainardi JL, Arthur M. Activation of the l,d-transpeptidation peptidoglycan cross-linking pathway by a metallo-d,d-carboxypeptidase in Enterococcus faecium. Mol Microbiol. 2010;75:874–885. doi: 10.1111/j.1365-2958.2009.07014.x. [DOI] [PubMed] [Google Scholar]
- 7.Dubée V, Arthur M, Fief H, Triboulet S, Mainardi JL, Gutmann L, Sollogoub M, Rice LB, Etheve-Quelquejeu M, Hugonnet JE. Kinetic analysis of Enterococcus faecium l,d-transpeptidase inactivation by carbapenems. Antimicrob Agents Chemother. 2012;56:3409–3412. doi: 10.1128/AAC.06398-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Dubée V, Triboulet S, Mainardi JL, Etheve-Quelquejeu M, Gutmann L, Marie A, Dubost L, Hugonnet JE, Arthur M. Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt1 by carbapenems and cephalosporins. Antimicrob Agents Chemother. 2012;56:4189–4195. doi: 10.1128/AAC.00665-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Mainardi JL, Hugonnet JE, Rusconi F, Fourgeaud M, Dubost L, Moumi AN, Delfosse V, Mayer C, Gutmann L, Rice LB, Arthur M. Unexpected inhibition of peptidoglycan l,d-transpeptidase from Enterococcus faeciumby the β-lactam imipenem. J Biol Chem. 2007;282:30414–30422. doi: 10.1074/jbc.M704286200. [DOI] [PubMed] [Google Scholar]
- 10.Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943–4960. doi: 10.1128/AAC.00296-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Biarrotte-Sorin S, Hugonnet JE, Delfosse V, Mainardi JL, Gutmann L, Arthur M, Mayer C. Crystal structure of a novel β-lactam-insensitive peptidoglycan transpeptidase. J Mol Biol. 2006;359:533–538. doi: 10.1016/j.jmb.2006.03.014. [DOI] [PubMed] [Google Scholar]
- 12.Bielnicki J, Devedjiev Y, Derewenda U, Dauter Z, Joachimiak A, Derewenda ZS. B. subtilis YkuD protein at 2.0 Å resolution: insights into the structure and function of a novel, ubiquitous family of bacterial enzymes. Proteins. 2005;62:144–151. doi: 10.1002/prot.20702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Erdemli SB, Gupta R, Bishai WR, Lamichhane G, Amzel LM, Bianchet MA. Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of l,d-transpeptidase 2. Structure. 2012;20:1–13. doi: 10.1016/j.str.2012.09.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Lecoq L, Bougault C, Hugonnet JE, Veckerlé C, Pessey O, Arthur M, Simorre JP. Dynamics induced by β-lactam antibiotics in the active site of Bacillus subtilis l,d-transpeptidase. Structure. 2012;20:850–861. doi: 10.1016/j.str.2012.03.015. [DOI] [PubMed] [Google Scholar]
- 15.Tipper D, Strominger J. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-d-alanyl-d-alanine. Proc Natl Acad Sci USA. 1965;54:1133–1141. doi: 10.1073/pnas.54.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Schüttelkopf AW, van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes, Acta Crystallogr. D Biol Crystallogr. 2004;60:1355–1363. doi: 10.1107/S0907444904011679. [DOI] [PubMed] [Google Scholar]
- 17.Brunger AT. Version 1.2 of the crystallography and NMR system. Nat Protoc. 2007;2:2728–2733. doi: 10.1038/nprot.2007.406. [DOI] [PubMed] [Google Scholar]
- 18.Triboulet S, Arthur M, Mainardi JL, Veckerle C, Dubée V, NGuekam-Moumi A, Gutmann L, Rice LB, Hugonnet JE. Inactivation kinetics of a new target of β-lactam antibiotics. J Biol Chem. 2011;286:22777–22784. doi: 10.1074/jbc.M111.239988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wider G, Weber C, Traber R, Widmer H, Wüthrich K. Use of a double-half-filter in two-dimensional 1H nuclear magnetic resonance studies of receptor-bound cyclosporin. J Am Chem Soc. 1990;112:9015–9016. [Google Scholar]
- 20.Shen Y, Delaglio F, Cornilescu G, Bax A. TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J Biomol NMR. 2009;44:213–223. doi: 10.1007/s10858-009-9333-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Guerry P, Herrmann T. Methods in Molecular Biology. Humana Press; 2011. Comprehensive automation for NMR structure determination of proteins; pp. 429–451. [DOI] [PubMed] [Google Scholar]
- 22.Rieping W, Habeck M, Bardiaux B, Bernard A, Malliavin TE, Nilges M. ARIA2: automated NOE assignment and data integration in NMR structure calculation. Bioinformatics. 2007;23:381–382. doi: 10.1093/bioinformatics/btl589. [DOI] [PubMed] [Google Scholar]
- 23.Doreleijers JF, Sousa da Silva AW, Krieger E, Nabuurs SB, Spronk CAEM, Stevens TJ, Vranken WF, Vriend G, Vuister GW. CING: an integrated residue-based structure validation program suite. J Biomol NMR. 2012;54:267–283. doi: 10.1007/s10858-012-9669-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wallace A, Laskowski R, Thornton J. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995;8:127–134. doi: 10.1093/protein/8.2.127. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.